POLBF (Poolbeg Pharma) Capex-to-Revenue : 0.00 (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Poolbeg Pharma Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Poolbeg Pharma's Capital Expenditure for the six months ended in Jun. 2024 was $-0.12 Mil. Its Revenue for the six months ended in Jun. 2024 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.

Poolbeg Pharma Capex-to-Revenue Historical Data

The historical data trend for Poolbeg Pharma's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poolbeg Pharma Capex-to-Revenue Chart

Poolbeg Pharma Annual Data

Trend

Dec21

Dec22

Dec23

Capex-to-Revenue

Poolbeg Pharma Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Capex-to-Revenue	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Poolbeg Pharma's Capex-to-Revenue

For the Biotechnology subindustry, Poolbeg Pharma's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poolbeg Pharma's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poolbeg Pharma's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Poolbeg Pharma's Capex-to-Revenue falls into.

Save Embed

;

Save Embed

;

Poolbeg Pharma Capex-to-Revenue Calculation

Poolbeg Pharma's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.222)	/	0
	=	N/A

Poolbeg Pharma's Capex-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.12)	/	0
	=	N/A

Poolbeg Pharma (OTCPK:POLBF) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Poolbeg Pharma Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Poolbeg Pharma's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Poolbeg Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poolbeg Pharma PLC (OTCPK:POLBF) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

POLB:UK 7JN:Germany

Address

42 New Road, Queen Mary BioEnterprises Innovation Centre, London, GBR, E1 2AX

Website

https://www.poolbegpharma.com

Poolbeg Pharma PLC is a clinical-stage infectious disease pharmaceutical company, with a novel capital-light clinical model which enables to develop of multiple products faster and more cost-effectively than the traditional biotech model. The company aspires to become a one-stop shop for pharma-seeking mid-stage products to license or acquire.